By Connor Hart
Scholar Rock named David Hallal as its chief executive, succeeding Jay Backstrom.
Hallal, who has served as chairman of the biopharmaceutical company's board since 2017, previously spent more than a decade holding executive positions at Alexion.
In the transition, Backstrom will move an advisory role and continue working with the company's executive team and board, Scholar Rock said Monday.
With the CEO transition, Scholar Rock said that Vikas Sinha will join as chief financial officer, R. Keith Woods has been appointed chief operating officer and Akshay Vaishnaw was named president of research and development.
Sinha formerly served as chief financial officer of Alexion and ElevateBio.
In the chief operating role, Woods will focus on evolving the company into what it called a fully-integrated global enterprise. He previously was chief operating officer of Argenx.
Vaishnaw will serve in the newly created role of president of research and development after previously serving as president of Alnylam.
Shares fell 1.5%, to $32.31, in pre-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 28, 2025 07:10 ET (11:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。